Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
Year: 2020
Type: article
Abstract: Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Institutions: Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Germano Oncologia, Universidade Federal do Rio de Janeiro, Complexo Hospitalar de Niterói, Universidade Federal da Bahia, Complexo Hospitalar Universitário Professor Edgard Santos, Universidade de São Paulo, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Beneficência Portuguesa de São Paulo, Universidade Federal de São Paulo, Hospital das Clínicas da Universidade Federal de Minas Gerais
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3024519712
